Han Orkun, Alci Aysun, Yildirim Hulya Tosun, Gokkaya Mustafa, Yalcin Necim, Kandemir Selim, Goksu Mehmet, Ureyen Isin, Toptas Tayfun
Department of Obstetrics and Gynecology, Saglik Bilimleri University Antalya Training and Research Hospital, 07100 Antalya, Turkey.
Department of Gynecological Oncology, Saglik Bilimleri University Antalya Training and Research Hospital, 07100 Antalya, Turkey.
Oncol Lett. 2024 Oct 2;28(6):580. doi: 10.3892/ol.2024.14713. eCollection 2024 Dec.
Determination of nuclear and/or cytoplasmic expression of β-catenin by immunohistochemistry in patients with endometrial cancer (EC) may constitute a potential diagnostic method for identifying patients with a catenin β1 (CTNNB1) gene mutation and those at risk of disease recurrence. The present study aimed to investigate β-catenin expression patterns in hysterectomy specimens of patients with endometrioid type EC using immunohistochemistry, and to examine the prognostic impact of β-catenin. The study was a single-institutional, retrospective cohort trial enrolling consecutive patients with a postoperative histopathological diagnosis of endometrioid EC who underwent hysterectomy between January 2015 and December 2018. Histopathology slides from 75 patients were stained with a monoclonal antibody targeting the β-catenin protein. Any percentage of nuclear staining, whether focal or diffuse, was considered 'β-catenin nuclear-positive'. The cytoplasmic staining reaction of β-catenin was assessed based on the percentage of stained cells and staining intensity. Immune-reactivity score (IRS) values were determined by multiplying the scores for the percentage of staining and staining intensity. IRS values 0 to 2 were regarded as negative expression, 3 to 4 as low expression, 6 to 8 as moderate expression, and 9 to 12 as high expression. Recurrence-free survival (RFS) was used as the prognostic endpoint. Only 2 out of 75 tissue samples (2.7%) exhibited nuclear β-catenin expression, with a low staining percentage of 5%. By contrast, cytoplasmic staining was observed in all samples (100%). According to the IRS findings, 1.3% of the samples exhibited negative cytoplasmic expression, 42.7% low expression, 38.7% moderate expression and 17.3% high expression. Cox regression analysis revealed that staining with β-catenin, either nuclear or cytoplasmic, had no impact on RFS, and stage was the sole independent prognostic factor. In conclusion, based on these results, β-catenin expression in endometrioid EC was revealed to be mostly cytoplasmic, with only 2.7% of tissue samples exhibiting nuclear expression. Overall, β-catenin expression has no impact on RFS.
通过免疫组织化学法测定子宫内膜癌（EC）患者中β-连环蛋白的细胞核和/或细胞质表达，可能构成一种潜在的诊断方法，用于识别患有连环蛋白β1（CTNNB1）基因突变的患者以及有疾病复发风险的患者。本研究旨在使用免疫组织化学法研究子宫内膜样型EC患者子宫切除标本中β-连环蛋白的表达模式，并探讨β-连环蛋白的预后影响。该研究是一项单机构回顾性队列试验，纳入了2015年1月至2018年12月期间接受子宫切除术且术后组织病理学诊断为子宫内膜样EC的连续患者。对75例患者的组织病理学切片用靶向β-连环蛋白的单克隆抗体进行染色。任何比例的细胞核染色，无论是局灶性还是弥漫性，均被视为“β-连环蛋白细胞核阳性”。根据染色细胞百分比和染色强度评估β-连环蛋白的细胞质染色反应。免疫反应评分（IRS）值通过将染色百分比得分与染色强度得分相乘来确定。IRS值0至2被视为阴性表达，3至4为低表达，6至8为中度表达，9至12为高表达。无复发生存期（RFS）用作预后终点。75个组织样本中只有2个（2.7%）表现出细胞核β-连环蛋白表达，染色百分比低至5%。相比之下，所有样本（100%）均观察到细胞质染色。根据IRS结果，1.3%的样本表现出细胞质阴性表达，42.7%为低表达，38.7%为中度表达，17.3%为高表达。Cox回归分析显示，β-连环蛋白的细胞核或细胞质染色对RFS没有影响，分期是唯一的独立预后因素。总之，基于这些结果，发现子宫内膜样EC中β-连环蛋白表达主要为细胞质，只有2.7%的组织样本表现出细胞核表达。总体而言，β-连环蛋白表达对RFS没有影响。
